Related Experiment Video
Updated: Apr 14, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Poly Beta-Amino Esters Nanoparticles as a Promising Strategy for Colon Cancer Therapy: Covering Synthesis Mechanisms,
Aakruti Shingare1, Sankha Bhattacharya2
1Department of Pharmaceutical Technology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Abstract:
Colon cancer is still one of the biggest health challenges globally, and most of the available treatments are hindered by drug resistance, systemic toxicity, and suboptimal efficacy. The Poly (beta-amino esters) (PBAE)-based nanoparticles have emerged as a promising nanotechnology-driven solution to these challenges. This review begins with the synthesis and functionalization of PBAE nanoparticles by focusing on polymerization techniques, targeting strategies, and scalability for clinical applications. The physicochemical properties of these nanoparticles, such as particle size, surface morphology, zeta potential, stability, biodegradability, and drug loading efficiency, are discussed in relation to their impact on therapeutic performance. Mechanistic insights into drug encapsulation, controlled release, tumour targeting, and the potential to overcome Multidrug Resistance (MDR) are also provided. Mechanistic insights are provided, including hydrophobic interaction-based drug encapsulation for efficient drug loading, pH-responsive controlled release in acidic tumor microenvironments, receptor-mediated tumour targeting using surface-functionalized ligands, and strategies to overcome Multidrug Resistance (MDR). Thereafter, preclinical studies are assessed, which include in-vitro cytotoxicity experiments and in-vivo animal models that test for efficacy, pharmacokinetics, and biodistribution. The review will then assess the status of PBAE nanoparticles in clinical trials, focusing on safety, efficacy, and the effects on patient outcomes in colorectal cancer treatment. Finally, regulatory approval, toxicity assessments, and commercialization challenges are discussed along with recommendations for overcoming these barriers. The review concludes by highlighting advancements in nanoparticle design, emerging therapeutic strategies, and the future potential of PBAE nanoparticles to transform colorectal cancer treatment.
Insights
Poly (beta-amino esters)-based nanoparticles offer a promising nanotechnology solution for colon cancer treatment, addressing challenges like drug resistance and toxicity. These nanoparticles demonstrate potential for improved drug delivery, tumor targeting, and overcoming multidrug resistance, paving the way for advanced colorectal cancer therapies.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Colorectal cancer presents significant global health challenges, with current treatments limited by drug resistance, toxicity, and efficacy issues.
- Poly (beta-amino esters)-based nanoparticles (PBAE NPs) are emerging as a novel nanotechnology-driven approach to overcome these limitations in cancer therapy.
Purpose of the Study:
- This review synthesizes current knowledge on PBAE NPs for colorectal cancer treatment.
- It covers synthesis, physicochemical properties, drug delivery mechanisms, preclinical and clinical studies, and commercialization challenges.
Main Methods:
- The review analyzes literature on PBAE NP synthesis, functionalization, characterization, and performance.
- It includes assessment of in vitro and in vivo studies, clinical trial data, and regulatory considerations.
Main Results:
- PBAE NPs show potential for efficient drug loading, pH-responsive controlled release, and targeted delivery to tumors.
- Mechanisms to overcome multidrug resistance (MDR) and promising results from preclinical and early clinical studies are highlighted.
Conclusions:
- PBAE nanoparticles represent a significant advancement in colorectal cancer treatment, offering improved efficacy and reduced toxicity.
- Further research and development are crucial for overcoming commercialization barriers and realizing their full therapeutic potential.
